Notice: This company has been marked as potentially delisted and may not be actively trading. Landos Biopharma (LABP) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends Institutional Ownership Changes (13F Filings) for Landos Biopharma (NASDAQ:LABP)CurrentInstitutional OwnershipPercentage49.06%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$1.61MNumber ofInstitutional Sellers(last 12 months)0 Get LABP Insider Trade Alerts Want to know when executives and insiders are buying or selling Landos Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LABP Institutional Buying and Selling by Quarter Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Landos Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/20/2024Virtu Financial LLC14,537$313K0.0%N/A0.464% 5/16/2024 Black Maple Capital Management LP10,405$223K0.1%N/A0.332% 4/17/2024 Deltec Asset Management LLC50,000$1.07M0.2%N/A1.603% 8/24/2023 Perceptive Advisors LLC1,486,991$6.26M0.2%-90.0%47.660% 11/14/2022 RTW Investments LP3,975,722$2.58M0.1%-7.0%9.876% 11/1/2022OUP Management Co. LLC1,237,667$804K1.3%-23.3%3.074% Get the Latest News and Ratings for LABP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter. 10/31/2022 Green Square Capital Advisors LLC84,500$55K0.0%N/A0.210% 7/19/2022OUP Management Co. LLC1,612,764$1.17M1.6%-11.7%4.006% 3/3/2022 Walleye Capital LLC105,208$505K0.0%N/A0.262% 2/10/2022 Acadian Asset Management LLC8,274$39K0.0%N/A0.021% 2/3/2022OUP Management Co. LLC1,827,478$8.77M4.0%N/A4.555% 11/12/2021 Geode Capital Management LLC112,933$1.65M0.0%-11.4%0.282% 11/12/2021 Botty Investors LLC128,750$1.88M0.6%+4.9%0.321% 11/9/2021BlackRock Inc.233,616$3.41M0.0%-20.6%0.582% 11/4/2021 Deutsche Bank AG2,693$39K0.0%-30.0%0.007% 11/2/2021 Cambridge Investment Research Advisors Inc.18,831$275K0.0%N/A0.047% 11/2/2021 New York State Common Retirement Fund2,756$40K0.0%-62.5%0.007% 11/2/2021 Allworth Financial LP5,286$77K0.0%N/A0.013% 10/22/2021 Strs Ohio11,400$166K0.0%+660.0%0.028% 8/17/2021 Logos Global Management LP899,106$10.39M0.9%+22.5%2.241% 8/16/2021 Tudor Investment Corp Et Al17,793$206K0.0%-71.3%0.044% 8/16/2021 State Street Corp92,367$1.07M0.0%+88.1%0.230% 8/13/2021 Botty Investors LLC122,781$1.42M0.5%+26.0%0.306% 8/13/2021 Geode Capital Management LLC127,518$1.47M0.0%+15.3%0.318% 8/13/2021 Vanguard Group Inc.305,185$3.52M0.0%+61.9%0.761% 8/11/2021 Bank of New York Mellon Corp14,029$162K0.0%+37.8%0.035% 8/11/2021BlackRock Inc.294,043$3.40M0.0%+14.7%0.733% 5/27/2021 Davidson Kempner Capital Management LP50,000$480K0.0%N/A0.125% 5/19/2021 Logos Global Management LP734,000$7.07M0.7%N/A1.830% 5/19/2021 Squarepoint Ops LLC15,361$148K0.0%N/A0.038% 5/18/2021 Zimmer Partners LP90,100$868K0.0%N/A0.225% 5/18/2021 Tudor Investment Corp Et Al61,899$596K0.0%N/A0.154% 5/18/2021 Orbimed Advisors LLC681,000$6.56M0.1%N/A1.697% 5/18/2021 Davidson Kempner Capital Management LP50,000$480K0.0%N/A0.125% 5/18/2021 Old Well Partners LLC18,316$176K0.1%N/A0.046% 5/18/2021 California State Teachers Retirement System9,518$92K0.0%N/A0.024% 5/17/2021 Deerfield Management Company L.P. Series C450,000$4.33M0.1%N/A1.122% 5/17/2021 Perceptive Advisors LLC17,960,839$159.69M2.0%N/A44.770% 5/17/2021 Woodline Partners LP213,335$2.05M0.0%N/A0.532% 5/17/2021 Caas Capital Management LP40,000$385K0.0%N/A0.100% 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link.5/17/2021 Nuveen Asset Management LLC10,219$98K0.0%N/A0.025% 5/17/2021 Sphera Funds Management LTD.70,000$674K0.1%N/A0.174% 5/14/2021 Laurion Capital Management LP10,000$96K0.0%N/A0.025% 5/14/2021 RTW Investments LP4,275,722$38.33M0.6%N/A10.658% 5/14/2021 Monashee Investment Management LLC91,309$879K0.1%N/A0.228% 5/13/2021 Bank of New York Mellon Corp10,182$98K0.0%N/A0.025% 5/13/2021 Botty Investors LLC97,477$939K0.3%N/A0.243% 5/12/2021 Northern Trust Corp74,359$716K0.0%N/A0.185% 5/12/2021 Geode Capital Management LLC110,559$1.06M0.0%N/A0.276% 5/12/2021 Ensign Peak Advisors Inc125,000$1.20M0.0%N/A0.312% 5/12/2021 JPMorgan Chase & Co.375,021$3.61M0.0%N/A0.935% 5/11/2021 Teacher Retirement System of Texas10,000$96K0.0%N/A0.025% 5/11/2021 New York State Common Retirement Fund7,300$70K0.0%N/A0.018% 5/7/2021BlackRock Inc.256,290$2.47M0.0%N/A0.639% 5/7/2021 American International Group Inc.3,677$35K0.0%N/A0.009% (Data available from 1/1/2016 forward) LABP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LABP shares? During the previous two years, the following institutional investors and hedge funds held shares of Landos Biopharma shares: Perceptive Advisors LLC ($6.26M), Deltec Asset Management LLC ($1.07M), and Virtu Financial LLC ($313K), Black Maple Capital Management LP ($223K).Learn more on LABP's institutional investors. What percentage of Landos Biopharma stock is owned by institutional investors? 49.06% of Landos Biopharma stock is owned by institutional investors. Learn more on LABP's institutional investor holdings. Which institutional investors have been buying Landos Biopharma stock? The following institutional investors have purchased Landos Biopharma stock in the last 24 months: Deltec Asset Management LLC ($50K), Virtu Financial LLC ($14.54K), and Black Maple Capital Management LP ($10.41K). How much institutional buying is happening at Landos Biopharma? Institutional investors have bought a total of 74,942 shares in the last 24 months. This purchase volume represents approximately $1.61M in transactions. Which Landos Biopharma major shareholders have been selling company stock? The following institutional investors have sold Landos Biopharma stock in the last 24 months: Perceptive Advisors LLC ($13.38M). How much institutional selling is happening at Landos Biopharma? Institutional investors have sold a total of 13,382,924 shares in the last 24 months. This volume of shares sold represents approximately $56.07M in transactions. Related Companies Achilles Therapeutics Major Shareholders Adverum Biotechnologies Major Shareholders TherapeuticsMD Major Shareholders Sensei Biotherapeutics Major Shareholders Aspira Women's Health Major Shareholders Gossamer Bio Major Shareholders Solid Biosciences Major Shareholders uniQure Major Shareholders Vanda Pharmaceuticals Major Shareholders Rezolute Major Shareholders This page (NASDAQ:LABP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Landos Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
